Dec 4, 2018
NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in RRMM Myeloma
NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Study of...
48